Oncological nanomedicine has progressively moved away from the single-agent paradigm toward integrated constructs in which diagnosis and therapy coexist within the same nanoscale entity. This is the theranostic rationale: a platform capable of localizing the lesion through imaging, modulating treatment according to the signal detected, and doing so with spatial selectivity. In this scenario, silk fibroin—a fibrous protein extracted from the cocoon of Bombyx mori—has established itself not as a mere biocompatible excipient but as an active matrix, capable simultaneously of organizing, reducing, stabilizing, and delivering the functional components of the nanosystem. It is worth examining why an ancient structural protein has become one of the most versatile molecular scaffolds in contemporary theranostics.
Fibroin as a molecular platform, not as an inert container
The distinctiveness of fibroin lies in its primary and secondary architecture. The heavy chain is dominated by repetitive motifs rich in glycine, alanine, and serine, which under appropriate conditions organize into antiparallel β-sheets (the crystalline conformation known as silk II), alternating with amorphous domains that confer flexibility and hydration. This coexistence of crystalline and amorphous regions makes fibroin amphiphilic and, above all, conformationally tunable: the random coil/α-helix to β-sheet transition can be induced by solvents, pH, shear forces, or thermal treatments, and directly governs the rate of enzymatic degradation, release kinetics, and colloidal stability of the final construct. In other words, by modulating the secondary structure, one programs the pharmaceutical behavior of the nanoparticle.
To this structural plasticity is added a generous surface chemistry. Tyrosine residues, carboxyl groups of aspartic and glutamic acid, and amino groups offer anchoring points for the conjugation of targeting ligands, contrast agents, and photosensitizers, without requiring exotic linkers. No less relevant is the redox role of the protein: aromatic residues and functional groups enable fibroin to act as a reducing and stabilizing agent in the in situ synthesis of metallic nanoparticles, enabling biomimetic one-pot protocols in aqueous environments that avoid toxic surfactants and reduce process complexity. The biological profile completes the picture: documented biocompatibility, biodegradability into metabolizable peptides and amino acids, low immunogenicity once sericin is removed, and intrinsic anti-inflammatory and immunomodulatory properties that contribute to the safety profile.
Fabrication and control of nanoscale properties
The translation of the protein into nanoparticles occurs through methodologies that critically determine size, polydispersity, surface charge, and crystalline content. Desolvation, through the addition of miscible organic solvents such as acetone or ethanol, remains the most widespread approach to induce self-assembly and β-sheet packing, often coupled with in situ polymerization when encapsulating a photoactive cargo. Alongside this are inverse microemulsion, useful for obtaining monodisperse populations and for fluorescent labeling, salting out, spray drying, and supercritical CO? techniques for more scalable processes. The control lever is crucial: the hydrodynamic size must remain within the window that favors passive tumor accumulation via the EPR effect while avoiding rapid reticuloendothelial clearance, while surface charge density and possible PEGylation or decoration with ligands (RGD peptides, folate, aptamers) determine circulatory half-life and cellular internalization. It is at this stage, and not downstream, that product reproducibility is established.
When the matrix becomes contrast: multimodal imaging
The first verb of theranostics is to see, and fibroin has proven to be an excellent scaffold for hosting complementary diagnostic signals. On the magnetic resonance imaging front, the protein can template the growth of metal oxides or host lanthanides: conjugated gadolinium generates T1 contrast with relaxivity competitive with commercial agents, while manganese dioxide grown by biomineralization on the nanoparticle behaves as an activatable contrast agent, since reduction to Mn²? in the glutathione-rich and acidic pH tumor microenvironment releases paramagnetic ions and, concurrently, oxygen. For computed tomography, gold nanoparticles nucleated by fibroin provide X-ray attenuation and thus radiographic contrast. On the optical side, the incorporation of indocyanine green or quantum dots enables near-infrared fluorescence and photoacoustic imaging, modalities that offer high spatial resolution and intraoperative guidance capability.
The added value lies not in the single modality but in their integration. A platform combining magnetic resonance imaging and computed tomography unites the former's excellent soft-tissue contrast with the latter's anatomical and quantitative resolution; the addition of a near-infrared fluorescence channel allows confirmation of EPR-mediated tumor enrichment and synchronization of therapeutic activation with the peak accumulation window. Imaging, in these constructs, is not descriptive but operational: it defines when and where to deliver the therapeutic dose.
Combination therapy and tumor microenvironment responsiveness
The second and third verbs—to hit and to do so selectively—find in fibroin an ideal scaffold for co-therapy. Photothermal therapy exploits the conversion of near-infrared radiation into heat by gold nanoparticles, indocyanine green, or polydopamine associated with the matrix, with documented photothermal conversion efficiencies, in fibroin-based systems loaded with chlorin e6 and irradiated at 808 nanometers, on the order of thirty percent. Photodynamic therapy, fueled by photosensitizers such as chlorin e6, generates cytotoxic reactive oxygen species and singlet oxygen, in synergy with photothermal hyperthermia. Conventional chemotherapy is integrated by encapsulating drugs within the nanoparticle with release triggered by tumor microenvironment stimuli, while chemodynamic approaches based on Fenton-type reactions expand the oxidative arsenal.
It is precisely the responsiveness to the tumor microenvironment that links imaging and therapy within a single logic. Extracellular and lysosomal acidosis, high glutathione concentration, hypoxia, and overexpression of specific enzymes become molecular switches that govern the conformational transition of fibroin, shell degradation, and cargo release. Manganese dioxide, in this scheme, is exemplary of a dual function: by reducing within the tumor it generates MRI contrast and, by releasing oxygen, attenuates hypoxia, which is known to limit the efficacy of photodynamic therapy. The platform, thus, does not merely transport: it reads the environment, reacts to it, and converts a diagnostic signal into a therapeutic action.
Paradigmatic architectures
Several constructs clearly illustrate the maturity of the field. Systems such as Gd:AuNPs@SF, obtained via a biomimetic one-pot route with fibroin simultaneously acting as reducing and stabilizing agent, integrate dual MRI and CT imaging with image-guided photothermal therapy, demonstrating tumor ablation in murine xenograft models without apparent systemic toxicity. Nanocomplexes that grow manganese dioxide on the fibroin nanoparticle and conjugate indocyanine green and a chemotherapeutic agent achieve genuinely trimodal theranostics, with combined MRI and near-infrared fluorescence imaging guiding a triple photothermal, photodynamic, and chemotherapeutic action. Fibroin nanocarriers loaded with chlorin e6, fabricated by desolvation and in situ polymerization and equipped with pH-responsive release, extend the same principle beyond oncology, to the photodynamic and photothermal eradication of drug-resistant bacteria and biofilms, showing how generalizable the platform truly is.
The translational bottleneck
It would be naive, and technically dishonest, to present this scenario as free of critical issues. The transition from preclinical model to clinic encounters the intrinsic variability of fibroin as a biological raw material: molecular weight, residual sericin content, and degree of crystallinity depend on the degumming protocol and the batch, and directly reflect on nanoparticle reproducibility. Physicochemical characterization must therefore be rigorous and standardized, and the scalability of synthesis processes must be demonstrated without loss of monodispersity. Open questions remain regarding long-term biological fate, the pharmacokinetics of inorganic components, clearance, and the immunological profile. Unsurprisingly, these are precisely the aspects that the regulatory frameworks applicable to devices and combined products require to be documented with solid evidence: the quality of the nanosystem, here, is not an academic attribute but the very prerequisite for its translatability.
Outlook
Silk fibroin condenses into a single molecule what theranostics demands of an ideal platform: biocompatibility, structural tunability, versatile conjugation chemistry, the ability to template contrast agents, and responsiveness to microenvironmental stimuli. Its strength is not any single exceptional performance, but the capacity to coherently and programmably integrate multimodal imaging and combination therapy. The challenge that will define the next decade is no longer to demonstrate that these constructs work in vivo, but to make them reproducible, scalable, and regulatory-robust. It is there, in the space between the elegance of the nanosystem and its industrialization, that fibroin will have to confirm that it is far more than a laboratory promise.
